In fact, the in vitro and in vivo results discussed above that have used genetic strategies to inhibit different galectin members (and in particular, Gal1, Gal3, or Gal9) have consistently demonstrated that depletion of these proteins impairs tumor progression, building the foundations for developing pharmacological inhibitors that could translate these results to cancer patients. The gene discussed is LGALS9; the disease is cancer.